Generic Truvada (Tenofovir + Emtricitabine)

Tenofovir disoproxil with emtricitabine is the active combination in Truvada®, used for HIV-1 treatment and for HIV pre-exposure prophylaxis (PrEP). Generic versions contain the same active ingredients at the same strengths and are produced by licensed pharmaceutical manufacturers, typically far below the originator price. Used as prescribed by a licensed medical professional.

Truvada® is the originator brand for the fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine, developed by Gilead Sciences. It is prescribed both as part of combination therapy for HIV-1 and as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1 in at-risk adults. It is a prescription-only medicine.

Tenofovir and emtricitabine are nucleos(t)ide reverse transcriptase inhibitors (NRTIs). They interfere with the reverse-transcriptase enzyme that HIV uses to copy itself. As PrEP, the combination is taken regularly as directed, alongside regular HIV testing and safer-sex measures, exactly as advised by your doctor.

This combination is prescribed for adults living with HIV-1 (as part of combination therapy) and for HIV-negative adults at risk of HIV who are suitable for PrEP, as determined by a doctor with appropriate testing.

The combination is usually taken as one tablet once daily, with or without food, at about the same time each day. For HIV treatment it is always combined with other antiretrovirals; for PrEP it is taken on an ongoing schedule alongside regular HIV testing and follow-up. Consistent daily dosing is important for it to work as intended.

Never change your dose on your own.

Reported side effects may include headache, nausea, diarrhoea, and tiredness, which often ease over time. Longer-term monitoring of kidney function and bone health is recommended, and anyone using it for PrEP must be confirmed HIV-negative beforehand and tested regularly, as your doctor will arrange.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

Brand Truvada was protected by patents for many years, which meant there was little price competition and the originator could command a premium. Truvada combines two established antiretrovirals — tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg — in a single daily tablet. Once licensed generic versions of that same combination became available, the cost fell sharply.

Generic tenofovir disoproxil fumarate/emtricitabine contains the identical active ingredients at the identical strengths, so it is expected to work the same way while costing substantially less. These medicines help manage HIV as part of combination therapy and are also used for pre-exposure prophylaxis; they do not cure HIV. A valid prescription and a clinician's assessment are required before starting or switching treatment.

Pricing varies by country, dose, and insurance status. Brand Truvada has indicatively cost around $2,000 per month in the United States and roughly £350 per month in the United Kingdom without insurance, while in Australia it is often subsidised. Generic tenofovir disoproxil fumarate/emtricitabine — the same 300 mg + 200 mg combination — is priced substantially lower, and current generic figures are shown on each product page below.

That large gap between brand and generic is what leads many people to ask their clinician about a licensed generic. Cost, however, is only one factor: the decision to start, continue, or switch this medicine should be made with a qualified healthcare professional, and it remains prescription-only whether it is used to manage HIV or for prevention.

Truvada and Descovy are often weighed against each other because both pair emtricitabine with a form of tenofovir — Truvada with tenofovir disoproxil fumarate and Descovy with tenofovir alafenamide. For people focused on cost, the practical difference is availability: licensed generic tenofovir disoproxil fumarate/emtricitabine has been on the market for years and is widely and affordably available, whereas lower-cost generic options for the Descovy combination remain more limited in many countries.

Both are used in HIV treatment and, in appropriate cases, for pre-exposure prophylaxis, where they reduce the risk of acquiring HIV when taken as prescribed and require a confirmed HIV-negative test result and ongoing testing. Which combination is appropriate — and whether a generic is suitable — depends on your kidney and bone health, other medicines, and individual circumstances, so it must be decided with your clinician. To compare the alternatives, see our generic Descovy page, and for prevention-specific guidance and pricing see our generic PrEP guide. Both options are prescription-only.